TONIX PHA.NEW2023 DL-,001
TONIX PHA.NEW2023 DL-,001
Action · US8902608541 · TNXP · A3EDH2 (XNCM)
Aperçu Indicateurs financiers
35,20 EUR
4,18 % 1,41 EUR
Frankfurt (XNAS) · Cours et graphiques actuels sur MoneyPeak
06.06.2025 23:59

Cours actuels de TONIX PHA.NEW2023 DL-,001

BourseTickerDeviseDernier échangeCoursVariation journalière
XNAS: NASDAQ
NASDAQ
TNXP
USD
06.06.2025 23:59
40,10 USD
38,39 USD
+4,45 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
-0,49 % 1,13 % 107,16 % 197,36 % 102,88 % -88,58 % -99,99 %

Profil de l'entreprise pour TONIX PHA.NEW2023 DL-,001 Action

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Données de l'entreprise

Nom TONIX PHA.NEW2023 DL-,001
Société Tonix Pharmaceuticals Holding Corp.
Symbole TNXP
Site web https://www.tonixpharma.com
Marché d'origine XNCM Frankfurt
WKN A3EDH2
ISIN US8902608541
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Dr. Seth Lederman M.D.
Capitalisation boursière 111 Mio
Pays États-Unis d'Amérique
Devise EUR
Employés 0,1 T
Adresse 26 Main Street, 07928 Chatham
Date d'introduction en bourse 2012-05-10

Fractionnements d'actions

Date Fractionnement
05.02.2025 1:100

Symboles boursiers

Nom Symbole
NASDAQ TNXP

Autres actions

Les investisseurs qui détiennent TONIX PHA.NEW2023 DL-,001 ont également les actions suivantes dans leur portefeuille :
E.ON SE MTN 19/31
E.ON SE MTN 19/31 Obligation
LB.HESS.THR.CARRARA03Q/25
LB.HESS.THR.CARRARA03Q/25 Obligation
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025